Allarta Life Science
Allarta Life Science is a pre-clinical stage life science company, with a proprietary platform technology to enable curative cell treatments for endocrine disorders such as Lysosomal Storage Disorders/Orphan Diseases, Diabetes and Hemophilia. Allarta is raising a Pre-Series A Bridge financing to support pre-clinical studies (diabetes), determining path to Orphan Drug cell models for small and large animal studies, and R&D investment on pipeline IP and core technologies within the company.
Presenter: Harald Stover, Co-Founder & CEO
Read More
Axolotl Biosciences
Axolotl Biosciences strives to advance the field of medical science through the use of our novel neurobioink. We are developing innovative products that enable the 3D bioprinting of humanized tissue models to advance the field of tissue engineering and regenerative medicine. Axolotl is opening the door to new areas of research by offering the (once impossible) ability to print stem cells into 3D structures.
Presenter: Dr. Stephanie Willerth, Co-Founder
Read More
Innovakine
Using cutting-edge protein and cell engineering approaches, Innovakine has developed a proprietary platform technology that allows clinicians to send exclusive, customized signals to immune cells and other cell types anywhere in the body, with broad clinical applications in the fields of cancer immunotherapy, infectious disease, autoimmunity, transplantation and regenerative medicine. Innovakine was founded in 2019 by Brad Nelson PhD (Distinguished Scientist, British Columbia Cancer; Professor, UBC) and Martin Boulanger PhD (Professor, University of Victoria) following a successful research collaboration with Zymeworks Inc., a clinical-stage biotechnology company. Innovakine is raising $4M in seed funding to complete pre-clinical POC studies in murine solid tumor models.
Presenter: Brad Nelson, Co-founder and CEO
Read More
Inspire Biotherapeutics
Inspire Biotherapeutics is a new company founded in partnership with The University of Guelph and The Ottawa Hospital Research Institute to develop and commercialize transformative gene therapies for currently incurable mono-genetic lung diseases. We have access to a GMP viral vector manufacturing facility and integrated research and clinical care platform. Our approach is based on recent successes in gene therapy development and commercialization: our proprietary, rationally designed adeno-associated virus (AAV) capsid, can be viewed as a next generation gene therapy and has many advantages over current products. Proceeds will be used to develop our first pipeline product to be tested in clinical trials by 2022.
Presenter: Bernard Thébaud, President
Read More
Jenthera Therapeutics
Jenthera Therapeutics is a seed stage therapeutics company introducing a novel protein-based gene editing platform delivering solutions to the major challenges currently facing CRISPR therapeutics: safety, precision corrections and targeted delivery. Our patented technology allows for the rapid development of high efficacy non-viral gene editing complexes achieving unprecedented levels of efficiency in cellular delivery, high frequencies of corrective precision repair and safety from off-target effects. We are looking to raise a 2M$ seed round to finance our EML4-ALK non-small cell lung cancer in vivo validation leading to a Series A in Q4-2021 that will fund IND enabling preclinical studies and PhaseI/II clinical trials.
Presenter: Philip Roche, CEO
Read More
Mediphage Bioceuticals
Mediphage Bioceuticals, a preclinical-stage biotechnology company, is developing the next-generation non-viral gene delivery platform based on its ministring DNA (msDNA) technology. Mediphage’s proprietary msDNA is a versatile gene delivery platform that has the potential for applications in various therapeutic areas including retina, liver, oncology, and CNS disorders among others. msDNA can be used in applications beyond gene therapy, including DNA vaccines to address infectious diseases, improved rAAV platform production, and gene editing. Mediphage is currently raising $32M CAD in Series A which will support executive and technical team growth, process development and proof of concept studies.
Presenter: Alvaro Amorrortu, CEO & President
Read More
Mesentech
Mesentech makes bi-specific small-molecule therapeutics that are selective for both a tissue target and a molecular target. These chemical conjugates liberate the active pharmaceutical only in the targeted tissue thereby eliminating side effects caused by systemic exposure. Mesentech’s lead program is a bone-targeted anabolic that stimulates bone regeneration. It is indicated for severe pediatric osteoporosis caused by brittle bone disease, Duchenne muscular dystrophy and as a consequence of steroid treatment.
Presenter: Jonathan Polak, CEO
Read More
Morphocell Technologies
Morphocell Technologies is a regenerative medicine company developing an extensive therapeutic platform based on its allogeneic stem cell-derived engineered liver tissues (ELT). Its mission is to transform the treatment of liver disease by the means of cell therapy. With $2.1M in pre-seed funding, we significantly de-risked the technology, collected compelling efficacy/safety data and addressed key scalability hurdles in manufacturing. We are seeking $4.5M to confirm the efficacy and safety of the ELT in large animals. Achieving this key value inflection point would trigger a larger series A investment from already engaged parties, thus enabling pre-clinical development up to CTA/IND application.
Presenter: Massimiliano Paganelli, Co-founder and CEO
Read More
Notogen
Notogen is a preclinical-stage biotechnology company developing a novel regenerative biologic therapy for degenerative disc disease (i.e. chronic back and neck pain caused by degenerating spinal discs), a disease indication with no disease modifying treatments that is the largest unmet need in orthopedics and one of the largest unmet needs in healthcare. Notogen has had a successful pre-IND meeting with the FDA, has published impressive large animal in vivo data, has raised funding to complete its cGMP manufacturing and its IND-filing, and is now looking to raise a Series A round to finance its Phase I/IIa clinical trial and beyond.
Presenter: Gary Margolis, CEO
Read More
PanTHERA CryoSolutions Inc
PanTHERA CryoSolutions Inc. (PanTHERA) is a Canadian Corporation that designs and manufacturers pre-formulated cryopreservation solutions for cells and tissues used in the clinical and research markets. The majority of cellular damage during cryopreservation occurs as a result of the uncontrolled growth of ice during storage at sub-zero temperatures followed by subsequent warming and thawing. The PanTHERA technology has the unique ability to control ice crystal size and growth throughout the cryopreservation process and thus maintain superior recoveries and cellular function after extended frozen storage.
Presenters: Robert Ben, Co-founder and CSO
Read More
Spiderwort
Spiderwort is an innovative pre-clinical stage tissue engineering company specializing in the development of cellulose-based biomaterials with a lead indication in Spinal Cord Injury repair with the ultimate goal to improve human quality of life. The FDA has granted a Breakthrough Device Designation for Spiderwort’s spinal cord technology. Spiderwort is raising Series A capital to support clinical pilot studies.
Presenter: Charles Cuerrier, CEO
Read More
